BBI503
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Urologic Malignancies
Conditions
Urologic Malignancies, Renal Cell Carcinoma, Urothelial Carcinoma
Trial Timeline
Jan 1, 2017 → Aug 1, 2018
NCT ID
NCT02232646About BBI503
BBI503 is a phase 2 stage product being developed by Sumitomo Pharma for Urologic Malignancies. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02232646. Target conditions include Urologic Malignancies, Renal Cell Carcinoma, Urothelial Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02232620 | Phase 2 | Terminated |
| NCT02232646 | Phase 2 | Withdrawn |
| NCT02432690 | Phase 2 | Terminated |
| NCT02232633 | Phase 2 | Completed |
| NCT01781455 | Phase 1 | Completed |
Competing Products
16 competing products in Urologic Malignancies
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| pemetrexed + cisplatin | Eli Lilly | Phase 1/2 | 41 |
| Mirabegron + Solifenacin succinate + Placebo | Astellas Pharma | Phase 2 | 52 |
| Mirabegron + Solifenacin succinate | Astellas Pharma | Phase 3 | 77 |
| Gemcitabine | Eli Lilly | Phase 2 | 52 |
| pemetrexed | Eli Lilly | Phase 2 | 52 |
| ALIMTA + gemcitabine | Eli Lilly | Phase 2 | 52 |
| Pembrolizumab Injection [Keytruda] | Merck | Phase 2 | 52 |
| Carboplatin/Paclitaxel + Pembrolizumab | Merck | Phase 2 | 52 |
| zoledronic acid | Novartis | Phase 2 | 52 |
| mycophenolate mofetil | Roche | Phase 1 | 33 |
| Cetuximab + Paclitaxel | Bristol Myers Squibb | Phase 2 | 51 |
| Nivolumab + Relatlimab | Bristol Myers Squibb | Phase 2 | 51 |
| CBT101 + Placebo | Brain Biotech | Phase 1 | 25 |
| OGX-427 600 mg + OGX-427 1000 mg + Placebo + Gemcitabine + Cisplatin + Carboplatin | Achieve Life Sciences | Phase 2 | 44 |
| S-8184 Paclitaxel Injectable Emulsion + Experimental Arm: TOCOSOL Paclitaxel | Achieve Life Sciences | Phase 2 | 44 |
| Stem Cell | Brain Biotech | Phase 1 | 25 |